Patients whose ALK-p NSCLC conditions have been treated with second-generation ALK inhibitors inevitably develop acquired resistance, and secondary acquired resistance mutations have been determined in approximately 50–70% of these patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.